4D Biomaterials secures £1.6m funding
4D Biomaterials, which has developed a new biomaterial used for 3D printing medical implants, has completed a £1.6m funding round.
The investment was led by DSW Ventures and backed by the MEIF Proof of Concept & Early Stage Fund, which is managed by Mercia and part of the Midlands Engine Investment Fund, Mercia’s own funds, and existing investor SFC Capital.
The funding will be used to develop a range of products through partnerships with medical device companies and expand its team with the creation of five new jobs at its premises in MediCity.
Dr James Lapworth, Warwick Innovations, who has worked closely with the founding team since 2017 to support their ICURe customer discovery process, said: “This oversubscribed investment round into 4D Biomaterials recognises the progress that the team has made since spinning out, as well as the market opportunities which the company’s unique range of biodegradable 3D printing materials could address.”
NanoSyrinx raises £6.2m to develop its synthetic biology platform for targeted intracellular engineering
Coventry, United Kingdom, 19th July 2021 – NanoSyrinx, a biotech company developing a new cell engineering tool for novel targeted therapeutic modalities, has raised a further £6.2m of seed financing, co-led by incoming Octopus Ventures and existing investor M Ventures (Amsterdam, The Netherlands), the corporate venture capital arm of Merck KGaA. Previous investors BioCity and the UK Innovation & Science Seed Fund (UKI2S) joined the funding round along with experienced deeptech investor IQ Capital and Jonathan Milner. The round was significantly oversubscribed with high demand both from existing and from new investors.
Dr James Lapworth, Warwick Innovations, who has worked closely with the founding team since 2016 to develop the commercialisation strategy for the technology, said: “This latest investment into NanoSyrinx is a huge vote of confidence in the technology and in the team. It recognises not only the potential impact that nanosyringes could have as advanced medicines but also the entrepreneurial talent emerging from our researcher community.”
For commercial enquiries contact Dr James Lapworth, Warwick Innovations, email: firstname.lastname@example.org
The University of Warwick spin-out company, CryoLogyx, has been awarded £300k from InnovateUK to develop innovate cryopreservation agents with applications in the diagnostic, medicines discovery and cell-based therapy markets.
For commercial enquiries contact Dr James Lapworth, Warwick Innovations, email: email@example.com, tel: + 44 (0)2476 575481